Loading market dashboard
Omnicell, Inc.
OMCLHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Robotics stocks like ABB gain traction as 2026 marks a surge in AI-driven automation, new cobots and strategic deals shaping the sector's next growth wave.
The average of price targets set by Wall Street analysts indicates a potential upside of 40.6% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
On June 04, 2026, Omnicell Inc (OMCL) shares rose 4.1% to a current price of $43.62. This performance comes amid a volatile trading period, with the stock's 52-
OMCL rides on SaaS growth, Autonomous Pharmacy adoption and expansion plans, but rising costs and competition could test its momentum.
After losing some value lately, a hammer chart pattern has been formed for Omnicell (OMCL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026.
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock?
OMCL shares soar 57.3% in a year as SaaS growth, Autonomous Pharmacy momentum and OmniSphere adoption boost outlook.
Omnicell, Inc. (OMCL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, OMCL's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
The average of price targets set by Wall Street analysts indicates a potential upside of 39.9% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Omnicell, Inc. (OMCL) Shareholder/Analyst Call Prepared Remarks Transcript
Omnicell, Inc. (OMCL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Does Omnicell (OMCL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Doximity, Veeva and Omnicell ride surging GenAI adoption in healthcare, tapping digital demand despite market pressure and rising cybersecurity risks.
Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
The mean of analysts' price targets for Omnicell (OMCL) points to a 41.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
OMCL posts Q1 earnings and revenue beat with surging margins and strong demand, sending shares sharply higher after results.
Omnicell provides automation and software solutions to streamline medication management for healthcare systems and pharmacies.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer.
Analysts underestimated its ability to grow revenue and profitability in the first quarter. Management also raised certain guidance items, including adjusted profitability.
On April 28, 2026, Omnicell Inc (OMCL) shares rose 20.9% to a current price of $45.51. This sharp increase follows a 52-week range where the stock has experienc
Investors looking for stocks in the Medical Info Systems sector might want to consider either Omnicell (OMCL) or Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?
Omnicell, Inc. (OMCL) Q1 2026 Earnings Call Transcript
Omnicell (OMCL) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.26 per share a year ago.
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces First Quarter 2026 Financial Results.
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release First Quarter 2026 Financial Results on April 28, 2026.
Tivic Health Systems (NASDAQ: TIVC - Get Free Report) and Omnicell (NASDAQ: OMCL - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations. Earnings and Valuation This table compares Tivic
Omnicell's autonomous pharmacy push and SaaS growth show promise, but rising costs and weak hospital spending cloud its near-term outlook.
Nyxoah (NASDAQ: NYXH - Get Free Report) and Omnicell (NASDAQ: OMCL - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation. Volatility and Risk Nyxoah has a beta of 1.56,
